Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sets New 52-Week High at $23.00

Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $23.00 and last traded at $22.67, with a volume of 76293 shares trading hands. The stock had previously closed at $16.83.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CALT shares. Citigroup upped their price target on shares of Calliditas Therapeutics AB (publ) from $76.00 to $79.00 and gave the stock a “buy” rating in a research report on Friday, February 24th. Guggenheim started coverage on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, February 28th. They set a “neutral” rating for the company. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Calliditas Therapeutics AB (publ) currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.00.

Calliditas Therapeutics AB (publ) Stock Performance

The company has a market cap of $736.61 million, a P/E ratio of -15.17 and a beta of 1.48. The company has a quick ratio of 4.33, a current ratio of 4.34 and a debt-to-equity ratio of 0.95. The company has a 50 day moving average price of $19.01 and a 200-day moving average price of $17.05.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Large investors have recently bought and sold shares of the stock. HBK Sorce Advisory LLC bought a new position in shares of Calliditas Therapeutics AB (publ) in the third quarter valued at approximately $50,000. Tower Research Capital LLC TRC boosted its stake in Calliditas Therapeutics AB (publ) by 1,270.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after purchasing an additional 3,112 shares in the last quarter. Optiver Holding B.V. raised its stake in shares of Calliditas Therapeutics AB (publ) by 1,304.3% in the 3rd quarter. Optiver Holding B.V. now owns 12,625 shares of the company’s stock worth $191,000 after buying an additional 11,726 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Calliditas Therapeutics AB (publ) by 7.6% in the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock worth $191,000 after buying an additional 886 shares in the last quarter. Institutional investors and hedge funds own 3.13% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.